A Chemist's Survey of Different Antibiotic Classes

Antibiotics: Targets, Mechanisms and Resistance

Volumn , Issue , 2013, Pages 1-22

  Maffioli, Sonia Ilaria ^a  

^a NAICONS Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884635939     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527659685.ch1     Document Type: Chapter

References (44)

1. Houghton, J.L., Green, K.D., Chen, W., and Garneau-Tsodikova, S. (2010) The future of aminoglycosides: the end or renaissance? ChemBioChem, 11, 880-902.
2. Endimiani, A., Hujer, K.M., Hujer, A.M., Armstrong, E.S., Choudhary, Y., Aggen, J.B., and Bonomo, R.A. (2009) ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant klebsiella pneumoniae isolates. Antimicrob. Agents Chemother., 53, 4504-4507.
3. Sutcliffe, J.A. (2011) Antibiotics in development targeting protein synthesis. Ann. N.Y. Acad. Sci., 1241, 122-152.
4. von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., and Habic, D. (2006) Antibacterial natural products in medicinal chemistry-hexodus or revival? Angew. Chem. Int. Ed., 45, 5072-5129.
5. Llarrull, L.I., Testero, S.A., Fisher, J.F., and Mobashery, S. (2010) The future of the β-lactams. Curr. Opin. Microbiol., 13, 551-557.
6. Butler, M.S. and Cooper, M.A. (2011) Antibiotics in the clinical pipeline in 2011. J. Antibiot., 64, 413-425.
7. Stachyra, T., Levasseur, P., Pechereau, M.C., Girard, A.M., Claudon, M., Miossec, C., and Black, M.T. (2009) In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother., 64, 326-329.
8. Pangborn, W.A., Duax, W.L., and Pletnev, V. (1999) Gramicidin D conformation, dynamics and membrane ion transport. Biopolymers, 51 (2), 129-144.
9. Parenti, F. and Cavalleri, B. (1989) Proposal to name the vancomycin like glycopeptides as dalbaheptides. J. Antibiot., 42 (12), 1882-1883.
10. Clardy, J., Fischbach, M.A., and Walsh, C.T. (2006) New antibiotics from bacterial natural products. Nat. Biotechnol., 24 (12), 1541-1550.
11. Donadio, S., Maffioli, S., Monciardini, P., Sosio, M., and Jabes, D. (2010) Antibiotic discovery in the twenty-first century: current trends and future perspectives. J. Antibiot., 63, 423-430.
12. Willey, J.M. and van der Donk, W.A. (2007) Lantibiotics: peptides with diverse structure and function. Annu. Rev. Microbiol., 61, 477-501.
13. Donadio, S., Maffioli, S., Monciardini, P., Sosio, M., and Jabes, D. (2010) Sources of novel antibiotics-aside the common roads. Appl. Microbiol. Biotechnol., 88, 1261-1267.
14. Jabes, D. and Donadio, S. (2010) Strategies for the isolation and characterization of antibacterial lantibiotics. Methods Mol. Biol., 618, 31-45.
15. Jabes, D., Brunati, C., Candiani, G., Riva, S., Romanò, G., and Donadio, S. (2011) Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant grampositive pathogens. Antimicrob. Agents Chemother., 55, 1671-1676.
16. Maffioli, S.I., Potenza, D., Vasile, F., De Matteo, M., Sosio, M., Marsiglia, B., Rizzo, V., Scolastico, C., and Donadio, S. (2009) Structure revision of the lantibiotic 97518. J. Nat. Prod., 79, 605-607.
17. Maffioli, S.I., Vasile, F., Potenza, D., Brunati, C., and Donadio, S. (2010) Lantibiotic carboxyamide derivatives with enhanced antibacterial activity. WO/2010/058238.
18. Mukhtar, T.A. and Wright, G.D. (2005) Streptogramins, oxazolidinones, and other inhibitors of bacterial protein synthesis. Chem. Rev., 105, 529-542.
19. He, H., Williamson, R.T., Shen, B., Graziani, E.I., Yang, H.Y., Sakya, S.M., Petersen, P.J., and Carter, G.T. (2002) Mannopeptimycins, novel antibacterial glycopeptides from streptomyces hygroscopicus LLAC98. J. Am. Chem. Soc, 124, 9729-9736.
20. Koehn, F.E. (2008) New strategies and methods in the discovery of natural product anti-infective agents: the mannopeptimycins. J. Med. Chem., 51, 2613-2617.
21. Velkov, T., Thompson, P.E., Nation, R.L., and Li, J. (2010) Structure-activity relationships of polymyxin antibiotics. J. Med. Chem., 53 (5), 1898-1916.
22. Landman, D., Georgescu, C., Martin, D.A., and Quale, J. (2008) Polymixins revisited. Clin. Microbiol. Rev., 21 (3), 449-465.
23. Vértesy, L., Ehlers, E., Kogler, H., Kurz, M., Meiwes, J., Seibert, G., Vogel, M., and Hammann, P. (2000) Friulimicins: novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from actinoplanes friuliensis sp. nov. II. Isolation and structural characterization. J. Antibiot., 53, 816-827.
24. Enoch, D.A., Bygott, J.M., Daly, M.-L., and Karas, J.A. (2007) Daptomycin. J. Infect., 55 (3), 205-213.
25. Fang, X., Nam, J., Shin, D., Rew, Y., Boger, D.L., and Walker, S. (2009) Functional and biochemical analysis of a key series of ramoplanin analogues. Bioorg. Med. Chem. Lett., 19, 6189-6191.
26. Ciabatti, R., Maffioli, S.I., Panzone, G., Canavesi, A., Michelucci, E., Tiseni, P.S., Marzorati, E., Checchia, A., Giannone, M., Jabes, D., Romanò, G., Brunet, C., Candiani, G., and Castiglione, F. (2007) Synthesis and preliminary biological characterization of new semisynthetic derivatives of ramoplanin. J. Med. Chem., 50, 3077-3085.
27. Xu, L., Farthing, A.K., Dropinski, J.F., Mainke, P.T., McCallum, C., Leavitt, P.S., Hickey, E.J., Colwell, L., and Liu, K. (2009) Nocathiacin analogs: synthesis and antibacterial activity of novel watersoluble amides. Bioorg. Med. Chem. Lett., 19, 3531-3533.
28. Morris, R.P., Leeds, J.A., Naegeli, L.O., Memmert, K., Weber, E., LaMarche, M.J., Parker, C.N., Burrer, N., Esterow, S., Hein, A.E., Schmitt, E.K., and krastel, P. (2009) Ribosomally synthesized thiopeptide antibiotics targeting elongation factor Tu. J. Am. Chem. Soc., 131, 5946-5955.
29. LaMarche, M.J., Leeds, J.A., Amaral, K., Brewer, J.T., Bushell, S.M., Dewhurst, J.M., Dzink-Fox, J., Gangl, E., Goldovitz, J., Jain, A., Mullin, S., Neckermann, G., Osborne, C., Palestrant, D., Patane, M.A., Rann, E.M., Sachdeva, M., Shao, J., Tiamfook, S., Whitehead, L., and Yu, D. (2011) Antibacterial optimization of 4-aminothiazolyl analogues of the natural product GE2270 A: identification of the cycloalkylcarboxylic acids. J. Med. Chem., 54, 8099-8109.
30. Mariani, R. and Maffioli, S.I. (2009) Bacterial RNA polymerase inhibitors: an organized overview of their structure, derivatives, biological activity and current clinical development status. Curr. Med. Chem., 16, 430-454.
31. Nelson, M.L. and Levy, S.B. (2011) The history of the tetracyclines. Ann. N.Y. Acad. Sci.-Antimicrob. Ther. Rev., 1241, 17-32.
32. Rose, W.E. and Rybak, M.J. (2006) Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy, 26 (8), 1009-1110.
33. Sun, C., Hunt, D.K., Clark, R.B., Lofland, D., O'Brien, W.J., Plamondon, L., and Xiao, X. (2011) Synthesis and antibacterial activity of pentacyclines: a novel class of tetracycline analogs. J. Med. Chem., 54, 3704-3731.
34. Barbachyn, M.R. and Ford, C.W. (2003) Oxazolidinone structure-activity relationships leading to linezolid. Angew. Chem. Int. Ed., 42, 2010-2023.
35. Leach, K.L., Brickner, S.J., Noe, M.C., and Miller, P.F. (2011) Linezolid, the first oxazolidinone antibacterial agent. Ann. N. Y. Acad. Sci., 1222, 49-54.
36. Vara Prasad, J.V.N. (2007) New oxazolidinones. Curr. Opin. Microbiol., 10, 454-460.
37. Sim, W.B., Choi, S.H., Park, J.Y., Choi, S.H., Finn, J., and Yoon, S.H. (2011) Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. Eur. J. Med. Chem., 46, 1027-1039.
38. Novak, R. (2011) Are Pleuromutilin antibiotics finally fit for human use? Ann. N. Y. Acad. Sci., 1241, 71-81.
39. Novak, R. and Shlaes, D.M. (2010) The pleuromutilin antibiotics: a new class for human use. Curr. Opin. Invest. Drugs, 11, 182-191.
40. Chu, D.T., Fernandes, P.B., Claiborne, A.K., Shen, L., and Pernet, A.G. (1988) Structure-activity relationships in quinolone antibacterials: design, synthesis, and biological activities of novel isothiazoloquinolones. Drugs Exp. Clin. Res., 14, 379-383.
41. Pucci, M.J., Podos, S.D., Thanassi, J.A., Leggio, M.J., Bradbury, B.J., and Deshpande, M. (2011) In vitro and in vivo profile of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob. Agents Chemother., 55, 2860-2871.
42. Black, M.T., Stachyra, T., Platel, D., Girard, A.M., Claudon, M., Bruneau, J.M., and Miossec, C. (2008) Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob. Agents Chemother., 52, 3339-3349.
43. Tse-Dinh, Y.C. (2007) Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect Disord.-Drug Targets, 7, 3-9.
44. Wolpert, M., Heide, L., Kammerer, B., and Gust, B. (2008) Assembly and heterologous expression of the coumermycin A1 gene cluster and production of new derivatives by genetic engineering. ChemBioChem, 9, 603-612.